Who is sponsoring NCT03843060?

NCT03843060 is sponsored by AstraZeneca.

What drugs are being tested in NCT03843060?

Interventions in NCT03843060: AZD9977, Itraconazole.

What condition does NCT03843060 study?

NCT03843060 studies Heart Failure With Preserved Ejection Fraction (HFpEF).

Is NCT03843060 still recruiting?

NCT03843060 is currently completed. Last updated 22 April 2019.

Last reviewed 2019-04-22 · How we verify

NCT03843060

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

Completed Phase 1 Last updated 22 April 2019

What this trial tests

Phase 1 trial testing AZD9977 in Heart Failure With Preserved Ejection Fraction (HFpEF) in 14 participants. Completed in 1 April 2019.

Timeline

22 February 2019

Primary endpoint
1 April 2019

1 April 2019

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	22 February 2019
Primary completion	1 April 2019
Estimated completion	1 April 2019
Sites	1 location across United States

Drugs / interventions tested

AZD9977 — full drug profile →
Itraconazole — full drug profile →

Conditions studied

Heart Failure With Preserved Ejection Fraction (HFpEF) — all drugs for Heart Failure With Preserved Ejection Fraction (HFpEF) →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, any sex, with Heart Failure With Preserved Ejection Fraction (HFpEF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies.
Ghatage T, Goyal SG, Dhar A, Bhat A. · · 2021 · cited 54× · PMID 33731923 · DOI 10.1038/s41440-021-00643-z
Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval.
Sundell J, Rekic D, Melin J, Johansson S, et al · · 2025 · cited 1× · PMID 39497618 · DOI 10.1002/psp4.13272
Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.
Parkinson J, Åstrand M, Melin J, Ericsson H. · · 2025 · PMID 40965596 · DOI 10.1007/s40262-025-01572-7

Verify or expand the search:

Other trials of AZD9977

Trials testing the same drug.

NCT04595370 — Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Dis · Phase 2 · completed
NCT04469907 — Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment · Phase 1 · completed
NCT03801967 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single · Phase 1 · completed
NCT03682497 — Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium · Phase 1 · terminated
NCT03435276 — Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subject · Phase 1 · completed

Other recruiting trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

Currently open trials in the same condition.

NCT06560762 — Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) · Phase 1 · recruiting
NCT05441839 — UK Heart Failure With Preserved Ejection Fraction · recruiting
NCT04822649 — Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition · NA · recruiting
NCT03876223 — Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03843060 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 22 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03843060.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing